A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.
about
Recent progress in West Nile virus diagnosis and vaccinationVaccine protection against Zika virus from BrazilVaccines in development against West Nile virusDengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral SerotypesVaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedlesPlant-made vaccines against West Nile virus are potent, safe, and economically feasibleEpidemiological and clinical aspects on West Nile virus, a globally emerging pathogen.Phase 1 study of pandemic H1 DNA vaccine in healthy adultsA Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics.Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.Rapid development of a DNA vaccine for Zika virusDNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trialCurrent trends in West Nile virus vaccine development.Targeting DNA vaccines to myeloid cells using a small peptide.Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trialThe efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeysPhase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.Novel vaccine strategies against emerging viruses.Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibodyWest Nile virus: A re-emerging pathogen revisited.A review of vaccine approaches for West Nile virus.Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.West Nile virus state of the art report of MALWEST Project.A review of the epidemiological and clinical aspects of West Nile virus.West Nile virus infection and immunity.An update on Zika vaccine developments.West nile virus infections in children.Technologies for the development of West Nile virus vaccines.Recent Developments in Preclinical DNA Vaccination.An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.Increasing plasmid-based DNA vaccine construct (16 kb pSVK-HBVA) production in Escherichia coli XL10-Gold through optimization of media component.Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein.High-Level Production of Plasmid DNA by Escherichia coli DH5α ΩsacB by Introducing inc Mutations.Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.DNA Vaccines: Recent Developments and the Future.
P2860
Q21284433-66CDA4EE-5135-4F09-8E5B-A767C55FF63EQ25165129-2B75F862-21B1-4877-A06D-49F46DD610ADQ26999702-8F8CDE10-05DF-4D4E-BB24-2AD9D6A91758Q27304342-AE67333E-BF7E-490A-97FB-D4165A930B1BQ27311290-865F2BD5-E6D3-429F-9608-01C58578C7D3Q28082778-3C559061-9DB7-49E5-ABF5-C0831E9CD450Q30250251-6739B197-8737-45A0-A41C-C2B8C5286B45Q30373824-C119DB79-18C2-4D1B-AD47-14449862C2F4Q30398406-62626196-61F0-46BB-8A7F-53B5DED3C4AEQ32183208-576438F7-D2BC-4045-B727-9408574BAE00Q33909344-2C9EBC63-CE9A-43C5-A28A-D82F62D1FDE9Q34263835-14800A9D-CD01-4A07-82A2-3ECE81EDAAEBQ34407701-DE2D73A6-3D8F-404B-B1DE-8463B1AFC4CEQ34542032-B2A73F82-8950-447B-B39D-89BCFDA907C0Q34663554-0B839A35-47D7-4ACD-ADA2-E7CC71248577Q34788758-92DD817B-C661-4DB6-AA9E-3343FB6CA34CQ34943809-58BA1422-CA4F-4A1F-A053-20515A3E77C6Q35055198-99332704-A44E-40AB-9B7C-6C1161C55471Q35492767-35969C21-E19B-41DB-AD80-5349409FD333Q36573064-4E1BFE41-614B-4B0F-989C-CFA60B757375Q36816140-530F355C-2532-4160-A4D9-51C007EDEEF5Q36974932-A560B78F-BCDB-4264-B359-142F33425553Q37123147-54B2027C-FD2F-4ECF-AD81-EFC1DDF98BADQ37195527-03D2EC1B-1956-40CC-964B-B53026C1848DQ37236968-4747EB9D-F896-4030-95B9-AD52CA65587EQ37276912-286FFD9E-D76A-416D-A7A1-0F54D6ED0368Q37434776-CF63ED14-9B94-489C-BA0C-B2D093D17CF7Q37708659-7E695585-ED27-4A3D-BBF5-8BA991A782C2Q38074266-B40EC493-A0FF-408E-98C2-3DB0F62C0092Q38158670-5A6A4586-7572-482E-A954-91AB8ED504DFQ38190430-F06EF1B6-31DF-4F78-8F02-D1F8AF88EFFDQ38269151-5729F2CD-11A0-421C-9DF2-D70A7E21D343Q38581976-A608151D-0959-4C21-900A-A7ADFE758321Q38866173-708C5186-1507-4F62-9026-BA6106A5FFE9Q41448201-E5A58730-72D9-4A2B-9552-02216AC3D4D7Q42235222-6B416F4B-DC73-4DD5-9CDE-7B97DB8B502BQ43045450-DB99C100-9F3C-41D1-8B1D-F342BD9DF919Q43047253-13AA1FA7-B25C-4418-9B57-9BD35BE71165Q44169836-AFDC0BF6-2AD8-45C8-945C-3076903EAE55Q45892465-EB24AEE5-18BC-43CA-8ECE-1E0561E766C6
P2860
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@ast
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@en
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@nl
type
label
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@ast
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@en
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@nl
prefLabel
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@ast
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@en
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@nl
P2093
P2860
P50
P921
P356
P1476
A West Nile virus DNA vaccine ...... s in a phase I clinical trial.
@en
P2093
Ingelise J Gordon
Martha Nason
Mary E Enama
Nikkida Bundrant
Niraj Desai
Richard A Koup
Robert T Bailer
Sarah A Hubka
Steevenson Nelson
Steve Rucker
P2860
P304
P356
10.1093/INFDIS/JIR054
P407
P577
2011-03-11T00:00:00Z